Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 3.04 MB
Add to list
  1. Search results
  2. Approaches to expand the conventional...

Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties

Hristo Svilenov (UGent) , Paolo Arosio, Tim Menzen, Peter Tessier and Pietro Sormanni
(2023) MABS. 15(1).
Author
Organization
Abstract
Antibody drugs should exhibit not only high-binding affinity for their target antigens but also favorable physicochemical drug-like properties. Such drug-like biophysical properties are essential for the successful development of antibody drug products. The traditional approaches used in antibody drug development require significant experimentation to produce, optimize, and characterize many candidates. Therefore, it is attractive to integrate new methods that can optimize the process of selecting antibodies with both desired target-binding and drug-like biophysical properties. Here, we summarize a selection of techniques that can complement the conventional toolbox used to de-risk antibody drug development. These techniques can be integrated at different stages of the antibody development process to reduce the frequency of physicochemical liabilities in antibody libraries during initial discovery and to co-optimize multiple antibody features during early-stage antibody engineering and affinity maturation. Moreover, we highlight biophysical and computational approaches that can be used to predict physical degradation pathways relevant for long-term storage and in-use stability to reduce the need for extensive experimentation.
Keywords
Immunology, Immunology and Allergy, candidate screening, early-stage screening, drug-like properties, manufacturability, developability, mAbs, Antibodies

Downloads

  • Download
    Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug like physicochemical properties (4).pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 3.04 MB

Citation

Please use this url to cite or link to this publication:

MLA
Svilenov, Hristo, et al. “Approaches to Expand the Conventional Toolbox for Discovery and Selection of Antibodies with Drug-like Physicochemical Properties.” MABS, vol. 15, no. 1, Informa UK Limited, 2023, doi:10.1080/19420862.2022.2164459.
APA
Svilenov, H., Arosio, P., Menzen, T., Tessier, P., & Sormanni, P. (2023). Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties. MABS, 15(1). https://doi.org/10.1080/19420862.2022.2164459
Chicago author-date
Svilenov, Hristo, Paolo Arosio, Tim Menzen, Peter Tessier, and Pietro Sormanni. 2023. “Approaches to Expand the Conventional Toolbox for Discovery and Selection of Antibodies with Drug-like Physicochemical Properties.” MABS 15 (1). https://doi.org/10.1080/19420862.2022.2164459.
Chicago author-date (all authors)
Svilenov, Hristo, Paolo Arosio, Tim Menzen, Peter Tessier, and Pietro Sormanni. 2023. “Approaches to Expand the Conventional Toolbox for Discovery and Selection of Antibodies with Drug-like Physicochemical Properties.” MABS 15 (1). doi:10.1080/19420862.2022.2164459.
Vancouver
1.
Svilenov H, Arosio P, Menzen T, Tessier P, Sormanni P. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties. MABS. 2023;15(1).
IEEE
[1]
H. Svilenov, P. Arosio, T. Menzen, P. Tessier, and P. Sormanni, “Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties,” MABS, vol. 15, no. 1, 2023.
@article{01GPZPXEEFBTDF75A9W1R0QTRY,
  abstract     = {{Antibody drugs should exhibit not only high-binding affinity for their target antigens but also favorable physicochemical drug-like properties. Such drug-like biophysical properties are essential for the successful development of antibody drug products. The traditional approaches used in antibody drug development require significant experimentation to produce, optimize, and characterize many candidates. Therefore, it is attractive to integrate new methods that can optimize the process of selecting antibodies with both desired target-binding and drug-like biophysical properties. Here, we summarize a selection of techniques that can complement the conventional toolbox used to de-risk antibody drug development. These techniques can be integrated at different stages of the antibody development process to reduce the frequency of physicochemical liabilities in antibody libraries during initial discovery and to co-optimize multiple antibody features during early-stage antibody engineering and affinity maturation. Moreover, we highlight biophysical and computational approaches that can be used to predict physical degradation pathways relevant for long-term storage and in-use stability to reduce the need for extensive experimentation.}},
  articleno    = {{2164459}},
  author       = {{Svilenov, Hristo and Arosio, Paolo and Menzen, Tim and Tessier, Peter and Sormanni, Pietro}},
  issn         = {{1942-0862}},
  journal      = {{MABS}},
  keywords     = {{Immunology,Immunology and Allergy,candidate screening,early-stage screening,drug-like properties,manufacturability,developability,mAbs,Antibodies}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{17}},
  publisher    = {{Informa UK Limited}},
  title        = {{Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties}},
  url          = {{http://doi.org/10.1080/19420862.2022.2164459}},
  volume       = {{15}},
  year         = {{2023}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: